Pactiv Evergreen Announces Expiration Of HSR Act Waiting Period For Acquisition By Novolex At $18/Share, Expected To Close In Q2 2025; Will Become Private, Nasdaq Delisting Expected Upon Transaction Completion

Author: Benzinga Newsdesk | January 21, 2025 09:12am

Pactiv Evergreen Inc. ("Pactiv Evergreen" or the "Company") (NASDAQ:PTVE) today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 in connection with the Company's previously announced definitive agreement to be acquired by Novolex® for $18.00 per share in cash.

The transaction is expected to close in the second quarter of 2025, subject to receipt of foreign antitrust approvals and satisfaction of other customary closing conditions. Upon the completion of the transaction, Pactiv Evergreen will become a privately held company, and its common stock will no longer be listed on Nasdaq.

Posted In: PTVE